Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Myrtho Branch

Child & Adolescent Psychiatry Orlando, FL Medical Doctor

NPI 1386675205 CMS profile 62449

2500 Discovery Dr, Orlando, FL 32826

Open in the dashboard

General payments

$5,051

189 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Myrtho Branch of Orlando, FL is reported in the CMS Open Payments database as having received $5,051 across 189 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,554 63
2024 General $635 30
2023 General $806 20
2022 General $603 21
2021 General $489 22
2020 General $382 16
2019 General $581 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Myrtho Branch
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Myrtho Branch were reported at $1,554. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Myrtho Branch Child & Adolescent Psychiatry median Middle half National median
2019 $581 $129 $42–$419 $163
2020 $382 $81 $28–$226 $114
2021 $489 $115 $31–$326 $132
2022 $603 $124 $40–$382 $149
2023 $806 $130 $45–$420 $160
2024 $635 $141 $42–$490 $164
2025 $1,554 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $895 32 payments
  2. ITI, Inc. $685 25 payments
  3. Janssen Pharmaceuticals, Inc $613 17 payments
  4. E.R. Squibb & Sons, L.L.C. $410 10 payments
  5. Ironshore Pharmaceuticals Inc. $303 11 payments
  6. Axsome Therapeutics, Inc. $233 5 payments
  7. AbbVie, Inc. $226 13 payments
  8. Neurocrine Biosciences, Inc. $209 8 payments
  9. Tris Pharma Inc $204 10 payments
  10. Corium, Inc. $193 11 payments
  11. Other $1,080 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,960 184 payments
  2. Education $91 5 payments
Products named General payments · program years 2019–2025
  1. ABILIFY MAINTENA $579 21 payments
  2. REXULTI $425 16 payments
  3. SPRAVATO $411 7 payments
  4. CAPLYTA Psychiatry $380 12 payments
  5. COBENFY $338 7 payments
  6. CAPLYTA Psychiatry $304 13 payments
  7. Auvelity $233 5 payments
  8. ABILIFY ASIMTUFII $210 10 payments
  9. VRAYLAR $208 12 payments
  10. INVEGA SUSTENNA $202 10 payments
  11. Other $2,570 112 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

1,030

Median for Psychiatry: 574

Drug cost

$49,439

Median for Psychiatry: $27,624

Branded share of claims

15.7%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 14 $14,448
Abilify Aripiprazole Brand 12 $7,823
Trintellix Vortioxetine Hydrobromide Brand 13 $6,313
Paliperidone Er Paliperidone Brand 39 $5,463
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 34 $2,440
Clozapine Generic 34 $1,882
Clonazepam Generic 105 $1,589
Aripiprazole Generic 27 $1,571
Perphenazine Generic 15 $1,386
Duloxetine Hcl Generic 50 $667

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $86
$86 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $77
$77 — —
COBENFY
  • E.R. Squibb & Sons, L.L.C. $72
$72 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $60
$60 14 —
INGREZZA
  • Neurocrine Biosciences, Inc. $55
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

189 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record